Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK-8644 · 1 trial · 2 indications
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention
| Arm | Type | Description |
|---|---|---|
| MK-8644 | EXPERIMENTAL | Participants receive MK-8644 orally under fasted or fed conditions depending on randomization. |
| Placebo | PLACEBO_COMPARATOR | Participants receive matching placebo for MK-8644 orally under fasted or fed conditions depending on randomization. |
| Name | Type | Description |
|---|---|---|
| MK-8644 | DRUG | Oral administration |
| Placebo for MK-8644 | DRUG | Oral administration |
Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Is in good health * Has a BMI between 18 and 36 kg/m\^2, inclusive Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * Has a history of clinically signific...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Johnson & Johnson | JNJ | 9 | PHASE3 | JNJ-77242113, Ustekinumab, Guselkumab |
| Bristol-Myers Squibb Company | BMY | 13 | PHASE3 | Deucravacitinib |
| AbbVie, Inc. | ABBV | 5 | PHASE3 | Risankizumab |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 2 | PHASE3 | Zasocitinib |
| Alumis Inc. | ALMS | 2 | PHASE3 | Envudeucitinib |
| Oruka Therapeutics, Inc. | ORKA | 4 | PHASE2 | ORKA-001, ORKA-002 |
| Can-Fite Biopharma Ltd | CANF | 1 | PHASE3 | Piclidenoson |
| Organon & Co. | OGN | 1 | PHASE3 | Tapinarof |
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE3 | Ponesimod |
| Novartis AG Sponsored ADR | NVS | 3 | - | Secukinumab |
| Bausch Health Companies Inc. | BHC | 2 | - | Brodalumab |
MK-8644 is an investigational small molecule being developed by Merck & Company, Inc. (ticker MRK) for psoriasis. It is in Phase 1 clinical development and has not been approved by the FDA. It is being studied in a single trial that includes both healthy participants and participants with psoriasis.
MK-8644 is being studied as a potential treatment for psoriasis. It is an investigational therapy in Phase 1 development, so its use is currently limited to clinical research. The ongoing trial enrolls adults with psoriasis alongside healthy participants to evaluate the drug.
MK-8644 is being developed by Merck & Company, Inc., which trades under the ticker MRK. Merck is the sponsor of the Phase 1 clinical program evaluating the small molecule in healthy participants and participants with psoriasis.
MK-8644 is in Phase 1 clinical development. It is an investigational small molecule and is not FDA approved. The program currently has one active trial, which has not yet started recruiting participants, and no completed trials.
MK-8644 is being evaluated in one clinical trial, NCT07850310, titled A Clinical Trial of MK-8644 in Healthy Participants and Participants With Psoriasis (MK-8644-001). The Phase 1 study is not yet recruiting, is placebo controlled, randomized, and double blind, and is planned to enroll 132 participants aged 18 years and older.